What is Relmada Therapeutics Inc's earnings per share (EPS)?

Relmada Therapeutics Inc (RLMD) reported diluted earnings per share of $-1.45 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Relmada Therapeutics Inc Financials

RLMD

Source SEC Filings (10-K/10-Q) Updated Mar 19, 2026 Currency USD FYE March

This page shows Relmada Therapeutics Inc (RLMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Relmada Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Relmada Therapeutics Inc generates $0.80 in operating cash flow (-$45.8M OCF vs -$57.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$57.4M

YoY+28.3%

Relmada Therapeutics Inc reported -$57.4M in net income in fiscal year 2025. This represents an increase of 28.3% from the prior year.

EPS (Diluted)

$-1.45

Relmada Therapeutics Inc earned $-1.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 45.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.5M

YoY-9.3%

5Y CAGR+7.0%

10Y CAGR-17.0%

Relmada Therapeutics Inc held $3.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

105M

Relmada Therapeutics Inc had 105M shares outstanding in fiscal year 2025. This represents an increase of 247.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-66.3%

YoY+158.8pp

5Y CAGR-10.0pp

10Y CAGR+169.8pp

Relmada Therapeutics Inc's ROE was -66.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 158.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.9M

YoY-41.8%

5Y CAGR-5.7%

10Y CAGR+13.1%

Relmada Therapeutics Inc invested $26.9M in research and development in fiscal year 2025. This represents a decrease of 41.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RLMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$26.9M-41.8%	$46.2M-15.7%	$54.8M-51.6%	$113.3M+25.1%	$90.6M+151.9%	$36.0M
SG&A Expenses	$32.2M-14.6%	$37.7M-22.9%	$48.9M+2.0%	$47.9M+36.6%	$35.1M+41.1%	$24.9M
Operating Income	-$59.1M+29.6%	-$83.9M+19.1%	-$103.7M+35.7%	-$161.2M-28.3%	-$125.7M-106.6%	-$60.8M
Interest Expense	N/A	N/A	$5.2M+93.7%	$2.7M+121.8%	$1.2M-14.3%	$1.4M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$57.4M+28.3%	-$80.0M+19.0%	-$98.8M+37.1%	-$157.0M-24.9%	-$125.8M-111.5%	-$59.5M
EPS (Diluted)	$-1.45	$-2.65+19.2%	$-3.28+38.1%	$-5.30+26.0%	$-7.16	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.0M+43.2%	$2.8M-76.4%	$12.0M	N/A	$11.1M+4.0%	$10.7M-19.4%	$13.3M	N/A
SG&A Expenses	$6.3M-15.0%	$7.4M+18.1%	$6.3M	N/A	$11.9M+46.5%	$8.1M-16.4%	$9.7M	N/A
Operating Income	-$10.3M-1.0%	-$10.2M+43.9%	-$18.2M	N/A	-$23.0M-22.3%	-$18.8M+18.1%	-$23.0M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$10.1M-2.3%	-$9.9M+43.8%	-$17.6M	N/A	-$21.7M-22.3%	-$17.8M+18.6%	-$21.8M	N/A
EPS (Diluted)	$-0.300.0%	$-0.30+48.3%	$-0.58	N/A	$-0.72-22.0%	$-0.59+18.1%	$-0.72	N/A

RLMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$94.0M+105.2%	$45.8M-53.0%	$97.6M-36.2%	$152.9M-31.5%	$223.3M+89.0%	$118.2M
Current Assets	$94.0M+105.2%	$45.8M-53.0%	$97.5M-36.2%	$152.9M-31.5%	$223.3M+89.1%	$118.1M
Cash & Equivalents	$3.5M-9.3%	$3.9M-5.7%	$4.1M-24.2%	$5.4M-87.9%	$44.4M+1681.0%	$2.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.5M-27.2%	$10.3M-15.6%	$12.2M-2.2%	$12.5M-17.2%	$15.1M+19.5%	$12.6M
Current Liabilities	$6.4M-37.5%	$10.3M-15.6%	$12.2M-2.2%	$12.5M-17.2%	$15.1M+19.5%	$12.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$86.5M+143.5%	$35.5M-58.4%	$85.4M-39.2%	$140.4M-32.6%	$208.3M+97.3%	$105.6M
Retained Earnings	-$698.3M-9.0%	-$640.9M-14.3%	-$560.9M-21.4%	-$462.1M-51.5%	-$305.1M-70.1%	-$179.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$14.9M-29.6%	$21.1M-23.7%	$27.7M-39.6%	$45.8M-17.8%	$55.7M-21.5%	$71.0M-15.9%	$84.4M-13.5%	$97.6M
Current Assets	$14.9M-29.6%	$21.1M-23.7%	$27.7M-39.6%	$45.8M-17.8%	$55.7M-21.5%	$71.0M-15.9%	$84.4M-13.5%	$97.5M
Cash & Equivalents	$1.4M+2.3%	$1.4M+17.7%	$1.1M-70.2%	$3.9M+159.9%	$1.5M-28.9%	$2.1M+56.3%	$1.3M-67.4%	$4.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.4M+4.7%	$5.2M-1.4%	$5.2M-49.1%	$10.3M+27.1%	$8.1M-15.1%	$9.5M-22.9%	$12.4M+1.4%	$12.2M
Current Liabilities	$5.2M+1.1%	$5.1M-1.9%	$5.2M-49.2%	$10.3M+27.3%	$8.1M-15.2%	$9.5M-22.9%	$12.4M+1.4%	$12.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.5M-40.7%	$15.9M-28.9%	$22.4M-36.8%	$35.5M-25.4%	$47.6M-22.6%	$61.5M-14.6%	$72.0M-15.6%	$85.4M
Retained Earnings	-$678.4M-1.5%	-$668.3M-1.5%	-$658.4M-2.7%	-$640.9M-3.0%	-$622.2M-3.6%	-$600.5M-3.0%	-$582.7M-3.9%	-$560.9M

RLMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$45.8M+11.5%	-$51.8M-0.2%	-$51.7M+50.2%	-$103.8M-13.0%	-$91.9M-230.4%	-$27.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$182.1M
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$209.9M
Investing Cash Flow	-$48.1M-193.4%	$51.6M+2.2%	$50.5M+155.7%	$19.7M+136.5%	-$54.1M-57.1%	-$34.4M
Financing Cash Flow	$93.6M+232034.8%	-$40K+59.0%	-$98K-100.2%	$45.0M-76.0%	$187.9M+560.1%	$28.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.7M-5.0%	-$6.4M+64.6%	-$18.1M-105.3%	-$8.8M+47.2%	-$16.7M-25.6%	-$13.3M-1.7%	-$13.0M-27.2%	-$10.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$6.8M+1.1%	$6.7M-56.5%	$15.4M+35.4%	$11.3M-29.7%	$16.1M+15.2%	$14.0M+39.3%	$10.1M+29.9%	$7.7M
Financing Cash Flow	$0	N/A	N/A	-$172K-92.5%	-$90K	$0-100.0%	$222K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RLMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-66.3%+158.8pp	-225.2%-109.4pp	-115.7%-3.9pp	-111.8%-51.5pp	-60.4%-4.1pp	-56.3%
Return on Assets	-61.1%+113.5pp	-174.6%-73.3pp	-101.3%+1.4pp	-102.7%-46.4pp	-56.3%-6.0pp	-50.3%
Current Ratio	14.62+10.2	4.45-3.5	8.00-4.3	12.26-2.6	14.83+5.5	9.37
Debt-to-Equity	0.09-0.2	0.29+0.1	0.14+0.1	0.09+0.0	0.07-0.0	0.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-106.6%-44.8pp	-61.9%+16.4pp	-78.3%	N/A	-45.6%-16.7pp	-28.9%+1.4pp	-30.3%	N/A
Return on Assets	-67.8%-21.1pp	-46.7%+16.7pp	-63.4%	N/A	-39.0%-14.0pp	-25.0%+0.8pp	-25.9%	N/A
Current Ratio	2.86-1.2	4.11-1.2	5.29+0.8	4.45-2.4	6.89-0.6	7.44+0.6	6.82-1.2	8.00
Debt-to-Equity	0.57+0.2	0.32+0.1	0.23-0.1	0.29+0.1	0.17+0.0	0.16-0.0	0.17+0.0	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Vtv Therapeutics VTVT

$162.2M

Actinium Pharmac ATNM

$30.8M

Veru VERU

$36.8M

Fibrogen Inc FGEN

$39.3M

Frequently Asked Questions

Is Relmada Therapeutics Inc profitable?

No, Relmada Therapeutics Inc (RLMD) reported a net income of -$57.4M in fiscal year 2025.

What is Relmada Therapeutics Inc's return on equity (ROE)?

Relmada Therapeutics Inc (RLMD) has a return on equity of -66.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Relmada Therapeutics Inc's operating cash flow?

Relmada Therapeutics Inc (RLMD) generated -$45.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Relmada Therapeutics Inc's total assets?

Relmada Therapeutics Inc (RLMD) had $94.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Relmada Therapeutics Inc spend on research and development?

Relmada Therapeutics Inc (RLMD) invested $26.9M in research and development during fiscal year 2025.

How many shares does Relmada Therapeutics Inc have outstanding?

Relmada Therapeutics Inc (RLMD) had 105M shares outstanding as of fiscal year 2025.

What is Relmada Therapeutics Inc's current ratio?

Relmada Therapeutics Inc (RLMD) had a current ratio of 14.62 as of fiscal year 2025, which is generally considered healthy.

What is Relmada Therapeutics Inc's debt-to-equity ratio?

Relmada Therapeutics Inc (RLMD) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Relmada Therapeutics Inc's return on assets (ROA)?

Relmada Therapeutics Inc (RLMD) had a return on assets of -61.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Relmada Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Relmada Therapeutics Inc (RLMD) had $3.5M in cash against an annual operating cash burn of $45.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Relmada Therapeutics Inc's Piotroski F-Score?

Relmada Therapeutics Inc (RLMD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Relmada Therapeutics Inc's earnings high quality?

Relmada Therapeutics Inc (RLMD) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.